GT201000179A - "antagonistas del receptor mineralcorticoide y metodos de uso" - Google Patents

"antagonistas del receptor mineralcorticoide y metodos de uso"

Info

Publication number
GT201000179A
GT201000179A GT201000179A GT201000179A GT201000179A GT 201000179 A GT201000179 A GT 201000179A GT 201000179 A GT201000179 A GT 201000179A GT 201000179 A GT201000179 A GT 201000179A GT 201000179 A GT201000179 A GT 201000179A
Authority
GT
Guatemala
Prior art keywords
mineralcorticoid
antagonists
receiver
methods
necessity
Prior art date
Application number
GT201000179A
Other languages
English (en)
Spanish (es)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201000179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201000179A publication Critical patent/GT201000179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
GT201000179A 2007-12-19 2010-06-17 "antagonistas del receptor mineralcorticoide y metodos de uso" GT201000179A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19

Publications (1)

Publication Number Publication Date
GT201000179A true GT201000179A (es) 2012-04-16

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000179A GT201000179A (es) 2007-12-19 2010-06-17 "antagonistas del receptor mineralcorticoide y metodos de uso"

Country Status (33)

Country Link
US (1) US7994164B2 (enExample)
EP (2) EP2537845B1 (enExample)
JP (1) JP5562866B2 (enExample)
KR (1) KR101254382B1 (enExample)
CN (1) CN101903377B (enExample)
AR (1) AR069554A1 (enExample)
AU (1) AU2008343524B2 (enExample)
BR (1) BRPI0820805A2 (enExample)
CA (1) CA2710409C (enExample)
CL (1) CL2008003600A1 (enExample)
CO (1) CO6300953A2 (enExample)
DK (1) DK2235007T3 (enExample)
DO (1) DOP2010000185A (enExample)
EA (1) EA017668B1 (enExample)
EC (2) ECSP10010266A (enExample)
ES (2) ES2459318T3 (enExample)
GT (1) GT201000179A (enExample)
HR (1) HRP20120916T1 (enExample)
IL (1) IL206353A (enExample)
MA (1) MA31910B1 (enExample)
MX (1) MX2010006911A (enExample)
MY (1) MY150474A (enExample)
NZ (1) NZ586300A (enExample)
PE (1) PE20091057A1 (enExample)
PL (1) PL2235007T3 (enExample)
PT (1) PT2235007E (enExample)
RS (1) RS52594B (enExample)
SI (1) SI2235007T1 (enExample)
TN (1) TN2010000292A1 (enExample)
TW (1) TWI431010B (enExample)
UA (1) UA100131C2 (enExample)
WO (1) WO2009085584A1 (enExample)
ZA (1) ZA201004257B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
WO2010104721A1 (en) * 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
EP2977084B1 (en) 2010-05-10 2017-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
WO2011157798A1 (en) 2010-06-16 2011-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
NZ712949A (en) 2013-05-02 2017-04-28 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
SI3160948T1 (sl) 2014-06-30 2020-06-30 Astrazeneca Ab Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida
NZ730759A (en) * 2014-11-21 2018-10-26 Lilly Co Eli 1,2-benzothiazole compounds for the treatment of kidney disorders
EP3362095B1 (en) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
ES2973248T3 (es) 2016-07-26 2024-06-19 Inst Nat Sante Rech Med Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis
MA45202B1 (fr) * 2016-09-24 2022-04-29 Kbp Biosciences Co Ltd Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) * 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
AR014195A1 (es) 1997-12-29 2001-02-07 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos
JP2002541144A (ja) 1999-01-26 2002-12-03 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 医薬的に活性のある化合物及びその使用方法
PL403800A1 (pl) * 2001-11-21 2013-08-19 Millennium Pharmaceuticals, Inc. Kompozycja farmaceutyczna
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
WO2005066153A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
CN1918151A (zh) 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
TWI400239B (zh) 2004-11-10 2013-07-01 Incyte Corp 內醯胺化合物及其作為醫藥品之用途
HRP20120078T1 (hr) 2006-10-31 2012-02-29 Pfizer Products Inc. Pirazolinski spojevi kao antagonisti mineralokortikoidnih receptora
US20100120736A1 (en) 2007-03-29 2010-05-13 N.V. Organon Mineralocorticoid Receptor Antagonists
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
US20100292233A1 (en) 2008-01-25 2010-11-18 Arena Pharmaceuticals, Inc. Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Also Published As

Publication number Publication date
IL206353A (en) 2014-06-30
EP2537845A1 (en) 2012-12-26
US7994164B2 (en) 2011-08-09
EA017668B1 (ru) 2013-02-28
UA100131C2 (uk) 2012-11-26
EP2537845B1 (en) 2014-03-19
TWI431010B (zh) 2014-03-21
MA31910B1 (fr) 2010-12-01
ES2459318T3 (es) 2014-05-09
CA2710409A1 (en) 2009-07-09
JP2011507868A (ja) 2011-03-10
WO2009085584A1 (en) 2009-07-09
DK2235007T3 (da) 2012-12-17
TN2010000292A1 (en) 2011-11-11
IL206353A0 (en) 2010-12-30
RS52594B (sr) 2013-04-30
ECSP12012048A (es) 2012-08-31
EP2235007A1 (en) 2010-10-06
PT2235007E (pt) 2013-01-22
DOP2010000185A (es) 2010-09-15
EP2235007B1 (en) 2012-10-31
AR069554A1 (es) 2010-02-03
AU2008343524A1 (en) 2009-07-09
EA201070762A1 (ru) 2010-12-30
MX2010006911A (es) 2010-10-05
CA2710409C (en) 2012-11-06
US20090163472A1 (en) 2009-06-25
KR20100082866A (ko) 2010-07-20
AU2008343524B2 (en) 2012-03-08
MY150474A (en) 2014-01-30
SI2235007T1 (sl) 2013-01-31
HRP20120916T1 (hr) 2012-12-31
ZA201004257B (en) 2011-11-30
KR101254382B1 (ko) 2013-04-15
ECSP10010266A (es) 2010-07-30
HK1144284A1 (en) 2011-02-11
NZ586300A (en) 2012-06-29
ES2396605T3 (es) 2013-02-22
CO6300953A2 (es) 2011-07-21
JP5562866B2 (ja) 2014-07-30
BRPI0820805A2 (pt) 2015-06-16
CN101903377B (zh) 2014-07-09
TW200930721A (en) 2009-07-16
CL2008003600A1 (es) 2010-02-19
PE20091057A1 (es) 2009-07-20
PL2235007T3 (pl) 2013-03-29
CN101903377A (zh) 2010-12-01

Similar Documents

Publication Publication Date Title
GT201000179A (es) "antagonistas del receptor mineralcorticoide y metodos de uso"
ECSP10010390A (es) Compuestos
UY32583A (es) Composiciones y métodos para aumentar el crecimiento muscular
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
AR072699A1 (es) Antagonistas especificos del receptor 4 del factor de crecimiento de los fi-broblastos (fgf-r4)
ECSP099435A (es) Compuestos agonistas de receptores esfingosina-1-fosfato y compuestos antagonistas
MX370000B (es) Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selectivos del receptor de nk-3, composición farmacéutica y métodos para su uso en trastornos mediados por el receptor de nk-3.
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
GT201300122A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
CL2008002450A1 (es) Compuestos derivados de fenil-pirrolidin-eter, con actividad antagonista de los receptores nk3; procedimientos para su preparacion; composicion farmaceutica; y el uso de los compuestos en el tratamiento de depresion, dolor, psicosis, entre otras.
UY32426A (es) Derivados bicilicos para uso en el tratamiento de enfermedades relacionadas al receptor de androgeno
EA201000316A1 (ru) Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
AR075260A1 (es) Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
CO6541592A2 (es) Tiazoles biciclicos como moduladores alostericos de receptores de mglur5
PA8781601A1 (es) " derivados de azaciclilbenzamida como antagonistas de histamina-3
PA8801501A1 (es) ARILINDENOPIRIMIDINAS Y SU USO COMO ANTAGONISTAS DEL RECEPTOR A 2a DE ADENOSINA
ECSP12011842A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS
ECSP12011840A (es) Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos
PA8769901A1 (es) Formulacion de pastillas de liberacion sostenida de antagonistas y agonistas de piperazina-piperidina del receptor 5-ht1a que tienen disolucion intestinal mejorada